The takeover is contingent upon a minimum acceptance rate of 65% and other conditions outlined in the offer document.
Novartis Initiates Voluntary Public Takeover of MorphoSys AG
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours